Dr. Jeffrey Peter Ward, MD

Dr. Ward practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Ward's NPI, 1356652176, was assigned on June 25, 2010. Dr. Ward holds Missouri license 2012012850.

Dr. Ward's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Ward also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Ward's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Ward is also affiliated with Missouri Baptist Medical Center. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Ward to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ward practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Ward's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Ward is licensed in Missouri.

CMS data shows 720 Medicare services from Dr. Ward across 10 procedure codes in 2024, for 126 Medicare patients. Medicare paid $23,256 for them.

CMS counts 126 Medicare patients who saw Dr. Ward in 2024. The largest group is 65 to 74, with 57 patients. 71% of them have cancer, and 71% have high blood pressure. 10% are also on Medicaid. Their average risk score is 2.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ward's median patient age at 71, with 47% women.

In 2024, Dr. Ward wrote 604 Medicare Part D claims for 67 patients. 86% of them were for generic drugs. CMS names the drug for 395 of them, across 14 drugs with 11 or more claims each, at $293,383 in total drug cost. In 2023, CMS named 318 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Ward for performance year 2024, reported as part of a group. Dr. Ward accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ward as offering telehealth.

Dmand AI links 23 papers to Dr. Ward, published from 2014 to 2024. 2021 was the busiest year, with 3. The most frequent topics are CD8-Positive T-Lymphocytes, Antigens, Neoplasm and Cell Line, Tumor. Dr. Ward has published most often in Cancer Immunol Res. Dr. Ward's most frequent co-authors are Daniel Morgensztern, MD, Siddhartha Harish Krishna Devarakonda, MD and Saiama Naheed Waqar, MD.

Dmand AI links Dr. Ward to 10 clinical trials, 4 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Mesothelioma, Malignant. Washington University School of Medicine sponsors the most, 5.

CMS Open Payments shows 36 general payments to Dr. Ward from 12 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 51% of the total. AstraZeneca Pharmaceuticals LP paid the most, $6,788. It also lists 1 research payment totaling $330 in 2023.